Humira

Humira is a biologic approved for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, Crohn's disease, and rheumatoid arthritis.

What is Humira?

Humira (also know by its generic name adalimumab) is a TNF-alpha inhibitor approved by the FDA in October 2005 for use in adult patients to treat active psoriatic arthritis and in January 2008 to treat moderate-to-severe psoriasis. It is also approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.

For adult patients with psoriatic arthritis, Humira is administered every other week. For adult patients with psoriasis, Humira is administered at week 0 and then every other week starting one week after initial dose. Humira is administered by injection under the skin.

To learn more, please visit the Humira website.

Treatment Pipeline

Learn about the latest treatment options currently in research.

Get the latest information
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Keep up to date with the psoriatic disease field.

Start reading

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.